Fosaprepitant

Drugbox
IUPAC_name = [3-{ [(2"R",3"S")-2- [(1"R")-1- [3,5-bis(trifluoromethyl)phenyl] ethoxy] -3-(4-fluorophenyl)morpholin-4-yl] methyl}-5-oxo- 2"H"-1,2,4-triazol-1-yl] phosphonic acid

---

CAS_number = 172673-20-0
CAS_supplemental = CAS|265121-04-8 (dimeglumine)
ATC_prefix = A04
ATC_suffix = AD12
PubChem = 219090
DrugBank =
C=23|H=22|F=7|N=4|O=6|P=1
molecular_weight = 614.406 g/mol
bioavailability = n/a
protein_bound = >95% (aprepitant)
metabolism = To aprepitant
elimination_half-life = 9 to 13 hours (aprepitant)
excretion =
pregnancy_AU =
pregnancy_US = B
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US = Rx-only
routes_of_administration = Intravenous
licence_EU =Ivemend
licence_US =Fosaprepitant

Fosaprepitant (INN; trade names Emend for Injection, Ivemend) is an anti-emetic drug, administered intravenously. It is a prodrug of aprepitant.

It was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008 . [cite web |url=http://www.drugs.com/newdrugs/fda-approves-emend-fosaprepitant-dimeglumine-merck-s-new-intravenous-therapy-combination-other-833.html |title=Drugs.com, FDA Approves Emend (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy |accessdate=2008-03-15 |format= |work= ] and by the European Medicines Agency (EMA) on January 11 of the same year. [cite web |url=http://www.emea.europa.eu/humandocs/Humans/EPAR/ivemend/ivemend.htm |title=European Public Assessment Report for Ivemend (from the EMEA website) |accessdate=2008-03-15 |format= |work= ]

References